DOBUTAMINE HYDROCHLORIDE

Post-LOE

dobutamine hydrochloride

Baxter

ANDAINJECTIONINJECTABLE

Approved

Sep 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DOBUTAMINE HYDROCHLORIDE (dobutamine hydrochloride) by Baxter is clinical pharmacology dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Approved for heart failure. First approved in 1996.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release…

Worked on DOBUTAMINE HYDROCHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DOBUTAMINE HYDROCHLORIDE

Mechanism of Action

Indications (1)